Biocept, Inc. (NASDAQ:BIOC) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Wednesday.

According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer. Biocept, Inc. is headquartered in San Diego, California. “

A number of other brokerages have also issued reports on BIOC. Chardan Capital reissued a “buy” rating and issued a $1.50 price objective (down from $2.50) on shares of Biocept in a report on Tuesday, November 14th. ValuEngine raised Biocept from a “strong sell” rating to a “sell” rating in a report on Monday, October 16th. Finally, Westpark Capital reissued an “outperform” rating on shares of Biocept in a report on Thursday, August 3rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $2.25.

Shares of Biocept (BIOC) opened at $0.62 on Wednesday. The company has a current ratio of 1.41, a quick ratio of 1.27 and a debt-to-equity ratio of 0.24. Biocept has a 1 year low of $0.60 and a 1 year high of $3.39.

COPYRIGHT VIOLATION NOTICE: “Zacks Investment Research Upgrades Biocept, Inc. (BIOC) to “Hold”” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at

A hedge fund recently raised its stake in Biocept stock. Creative Planning increased its holdings in Biocept, Inc. (NASDAQ:BIOC) by 64,679.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 246,811 shares of the medical research company’s stock after buying an additional 246,430 shares during the quarter. Creative Planning owned about 0.93% of Biocept worth $338,000 at the end of the most recent reporting period. 7.75% of the stock is currently owned by institutional investors and hedge funds.

About Biocept

Biocept, Inc is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.

Receive News & Stock Ratings for Biocept Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept Inc. and related stocks with our FREE daily email newsletter.